Similar articles for PMID: 14754606

Year	Number of Results
1962	1
1970	1
1971	1
1983	1
1989	3
1990	4
1991	1
1992	3
1993	1
1994	3
1995	1
1996	2
1997	2
1998	4
1999	6
2000	11
2001	7
2002	20
2003	57
2004	20
2005	17
2006	19
2007	13
2008	14
2009	11
2010	15
2011	17
2012	11
2013	15
2014	9
2015	7
2016	3
2017	1
2018	1
2020	2
2021	1
2022	1
2024	0

1

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW. Lange T, et al. Haematologica. 2004 Jan;89(1):49-57. Haematologica. 2004. PMID: 14754606

2

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC. Frater JL, et al. Am J Clin Pathol. 2003 Jun;119(6):833-41. doi: 10.1309/A4RG-P4LF-12GG-H8MW. Am J Clin Pathol. 2003. PMID: 12817431 Clinical Trial.

3

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].

Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP. Qin YZ, et al. Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 15946498 Chinese.

4

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP; International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Hughes TP, et al. N Engl J Med. 2003 Oct 9;349(15):1423-32. doi: 10.1056/NEJMoa030513. N Engl J Med. 2003. PMID: 14534335 Free article. Clinical Trial.

5

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Iacobucci I, et al. Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574. Clin Cancer Res. 2006. PMID: 16707599 Clinical Trial.

6

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Cortes J, et al. Clin Cancer Res. 2005 May 1;11(9):3425-32. doi: 10.1158/1078-0432.CCR-04-2139. Clin Cancer Res. 2005. PMID: 15867244 Clinical Trial.

7

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Merx K, et al. Leukemia. 2002 Sep;16(9):1579-83. doi: 10.1038/sj.leu.2402680. Leukemia. 2002. PMID: 12200666 Clinical Trial.

8

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.

Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Kolb EA, et al. Cancer. 2003 Dec 15;98(12):2643-50. doi: 10.1002/cncr.11895. Cancer. 2003. PMID: 14669284 Free article. Review.

9

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Paschka P, et al. Leukemia. 2003 Sep;17(9):1687-94. doi: 10.1038/sj.leu.2403033. Leukemia. 2003. PMID: 12970765

10

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.

Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Kantarjian H, et al. Cancer. 2003 Oct 1;98(7):1430-7. doi: 10.1002/cncr.11665. Cancer. 2003. PMID: 14508830 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

287 results

Results by year